Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Subcutaneous versus intravenous daratumumab administration in patients with relapsed or refractory multiple myeloma

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.19
Views: 577
Rating:

Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain

Prof Maria-Victoria Mateos talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the COLUMBA study into subcutaneous versus intravenous daratumumab administration in patients with relapsed or refractory multiple myeloma.

She explains that the conventional use of daratumumab currently is intravenous and although this setting has demonstrated safety and effectiveness, it takes a long time to administer.

Prof Mateos reports that the subcutaneous administration of daratumumab was shown to be effective and safe, meeting the efficacy and PK co-primary endpoints demonstrating non-inferiority.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation